ORMP

Company Overview — What Does ORAMED PHARMACEUTICALS INC. Do?

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. ORAMED PHARMACEUTICALS INC. (ORMP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Nadav Kidron and employs approximately 10 people, headquartered in JERUSALEM, New York. With a market capitalization of $137M, ORMP is one of the notable companies in the Healthcare sector.

ORAMED PHARMACEUTICALS INC. (ORMP) Stock Rating — Reduce (April 2026)

As of April 2026, ORAMED PHARMACEUTICALS INC. receives a Reduce rating with a composite score of 34.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ORMP ranks #2,966 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ORAMED PHARMACEUTICALS INC. ranks #423 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ORMP Stock Price and 52-Week Range

ORAMED PHARMACEUTICALS INC. (ORMP) currently trades at $3.53. The stock gained $0.01 (0.3%) in the most recent trading session. The 52-week high for ORMP is $3.76, which means the stock is currently trading -6.1% from its annual peak. The 52-week low is $1.82, putting the stock 94.0% above its annual trough. Recent trading volume was 56K shares, suggesting relatively thin trading activity.

Is ORMP Overvalued or Undervalued? — Valuation Analysis

ORAMED PHARMACEUTICALS INC. (ORMP) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 4.14x, compared to the Healthcare sector average of 23.63x — a discount of 82%. The price-to-book ratio stands at 0.71x, versus the sector average of 2.75x. The price-to-sales ratio is 71.19x, compared to 1.66x for the average Healthcare stock.

At current multiples, ORAMED PHARMACEUTICALS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ORAMED PHARMACEUTICALS INC. Profitability — ROE, Margins, and Quality Score

ORAMED PHARMACEUTICALS INC. (ORMP) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 17.2%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 14.9% versus the sector average of -33.1%.

On a margin basis, ORAMED PHARMACEUTICALS INC. reports gross margins of 0.7%, compared to 71.5% for the sector. The operating margin is -225.0% (sector: -66.1%). Net profit margin stands at -382.1%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ORMP Debt, Balance Sheet, and Financial Health

ORAMED PHARMACEUTICALS INC. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.98x, indicating strong short-term liquidity. Total debt on the balance sheet is $1,000. Cash and equivalents stand at $52M.

ORMP has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ORAMED PHARMACEUTICALS INC. is 62/100, reflecting average volatility within the normal range for its sector.

ORAMED PHARMACEUTICALS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ORAMED PHARMACEUTICALS INC. reported revenue of $2M and earnings per share (EPS) of $1.53. Net income for the quarter was $34M. Gross margin was 0.7%. Operating income came in at $-13M.

In FY 2025, ORAMED PHARMACEUTICALS INC. reported revenue of $2M and earnings per share (EPS) of $1.53. Net income for the quarter was $64M. Gross margin was 0.7%. Operating income came in at $-15M.

In Q3 2025, ORAMED PHARMACEUTICALS INC. reported revenue of $0 and earnings per share (EPS) of $1.16. Net income for the quarter was $48M. Operating income came in at $-2M.

In Q2 2025, ORAMED PHARMACEUTICALS INC. reported revenue of $0 and earnings per share (EPS) of $0.32. Net income for the quarter was $13M. Operating income came in at $-2M.

Over the past 8 quarters, ORAMED PHARMACEUTICALS INC. has reported varying levels of revenue. Investors analyzing ORMP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ORMP Dividend Yield and Income Analysis

ORAMED PHARMACEUTICALS INC. (ORMP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ORMP Momentum and Technical Analysis Profile

ORAMED PHARMACEUTICALS INC. (ORMP) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ORMP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ORAMED PHARMACEUTICALS INC. (ORMP) ranks #423 out of 838 stocks based on the Blank Capital composite score. This places ORMP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ORMP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ORMP vs S&P 500 (SPY) comparison to assess how ORAMED PHARMACEUTICALS INC. stacks up against the broader market across all factor dimensions.

ORMP Next Earnings Date

No upcoming earnings date has been announced for ORAMED PHARMACEUTICALS INC. (ORMP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ORMP? — Investment Thesis Summary

The quantitative profile for ORAMED PHARMACEUTICALS INC. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers. Low volatility (stability score 62/100) reduces downside risk.

In summary, ORAMED PHARMACEUTICALS INC. (ORMP) earns a Reduce rating with a composite score of 34.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ORMP stock.

Related Resources for ORMP Investors

Explore more research and tools: ORMP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ORMP head-to-head with peers: ORMP vs AZN, ORMP vs SLGL, ORMP vs VMD.